pharmaphorum7mon
Novartis gets FDA OK for first in its trio of IgAN therapies
Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
pharmaphorum5d
CSL, Travere close on EU approval of IgAN drug sparsentan
The CHMP has recommended approval of sparsentan for the treatment of primary IgAN – a rare kidney disorder and a leading cause of kidney failure – in adults with a urine protein excretion ...
Yahoo Finance9d
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy
BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence ...
Nature3mon
The Oxford classification—predicting progression of IgAN
The IgAN group needs to be congratulated for coordinating a worldwide effort to develop a universally accepted IgAN classification system. By developing agreed definitions for each pathological ...
Nature3y
Breaking new ground with a late-phase rare-disease pipeline
Having been the first company to deliver positive phase 3 data in the rare disease immunoglobulin A nephropathy (IgAN), Calliditas is awaiting regulatory approval decisions in the US and European ...